Biogen Idec seeks costs savings in HQ relocation
This article was originally published in Scrip
Executive Summary
Biogen Idec is to relocate its corporate headquarters to reduce costs. The firm said that it would move its general and administration operations to a 350,000ft2 facility in the cheaper suburbs of Massachusetts. The firm's head office will remain in Massachusetts, but will move from Cambridge to Weston. "The Weston site gives us the flexibility to allow [Biogen Idec] the future growth in an area where commercial real estate is less expensive," the company told Scrip. The move, which will affect up to 600 employees, follows a regular review of Biogen Idec's operations and will be completed during the second half of 2010. No employees will be laid off as part of the relocation and its site in Cambridge will remain operational. Biogen Idec said that the vacated space at Cambridge would be used to house other parts of the company's functions.
You may also be interested in...
AB Science lists on Euronext after reducing offer size
AB Science has closed its IPO at just half of the value of its initial expectations. The gross proceeds of the French firm's offer were €27.5 million, compared with the €55.5 million it anticipated when it filed for the offering on 8 April. Of the total, the company secured $16.5 million from the sale of newly issued shares; the remaining €11 million went to selling shareholders.
Amgen posts strong first-quarter sales but healthcare reform set to bite
Amgen's sales rebounded in the first quarter rising 9% to $3.6 billion after a disappointing end to last year. However, the introduction of new legislation for US healthcare has weighed on its forecast for the year, as it has done for many of its competitors.
Tracleer drives growth for Actelion
Actelion's total revenues leapt up by 24% to CHF502 million ($467 million) during the first quarter due to stronger demand for its pharmaceuticals. The firm's net income rose by 30% to CHF133 million, while its diluted EPS increased from CHF0.83 in the first quarter last year to CHF1.09.